Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia: Analysis of the clinico-pathological aspects of documented acute anthracycline-induced cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zürich, Switzerland, bet ween 1990 and 1996 by Dazzi, H. et al.
Annals of Oncology 12: 963-966. 2001.
© 2001 Kluwer Academic Publishers, Primed in the Netherlands
Original article
Anthracycline-induced acute cardiotoxicity in adults treated for leukaemia
Analysis of the clinico-pathological aspects of documented acute anthracycline-induced
cardiotoxicity in patients treated for acute leukaemia at the University Hospital of Zurich,
Switzerland, between 1990 and 1996
H. Dazzi, K. Kaufmann & F. Follath
Department for Internal Medicine. University Hospital. Zurich, Switzerland
Summary
Background: Acute cardiotoxicity due to anthracyclines is a
rare, but life-threatening event. Interindividual sensitivity to
anthracyclines is highly variable and cannot be predicted for
the individual patient.
Patients and methods:_ThisJ_s aj^etrosgective study. Medical
charts and autopsy reports of patients treated for acute leuke-
mia between 1990 and 1996 at the University Hospital of
Zurich, Switzerland were reviewed and searched for anthra-
cycline-associated acute cardiotoxicity. Patients with pre-exist-
ing heart disease known to be associated with cardiotoxicity
were excluded.
Results: Seven patients treated for leukemia with proven
anthracycline-associated acute cardiotoxicity were included.
In six patients the direct cause of death was acute cardiotox-
icity due to the treatment. One patient recovered from cardiac
failure but died a few months later from refractory leukemia.
Clinical symptoms were those of a heart failure. Pathological
findings were dilatative cardiac hypertrophy and pericardial
effusion. Microscopically the typical findings of myocardial
fibrosis and perinuclear vacuolisated myocytes were seen.
Conclusions: The awareness of acute adverse effects on
cardiac performance by anthracyclines faciliates early recog-
nition and prevention of heart failure. Reliable tests are needed
for the early diagnosis of subclinical myocardial damage in
order to identify patients at risk.
Key words: anthracycline-associated acute cardiotoxicily, clin-
ical symptoms, pathological findings
Introduction
Anthracyclines, most commonly daunorubicin, idarubi-
cin or mitoxantrone are highly efficacious antineoplastic
agents for acute myeloid leukemia (AML). However,
their therapeutic potential is limited by the ocurrence of
cardiotoxicity [1-6].
Three distinct types of anthracycline-induced cardio-
toxicity have been described [7]. Chronic cardiotoxicity
resulting in cardiomyopathy is well known and clini-
cally the most important form [2, 10]. Chronic cardio-
myopathy usually occures within one year of treatment
[2]. The cumulative dose is a well known important risk
factor. Today, late onset of anthracycline-induced
cardiotoxicity causing ventricular dysfunction [11-13]
and arrhythmia [14-16] is recognised more often than
earlier. Its manifestations occure years or decades after a
prolonged asymptomatic period.
The acute injury becomes clinically manifest during
or immediately after anthracycline administration long
before the assumed total cumulative toxic dose is
reached. However, with the current cytotoxic drug regi-
mens it is thought to be a relatively rare unwanted side
effect. Clinicians are often not aware of the potential risk
and less severe episodes are most likely missed. Acute
cardiotoxicity presents mainly with transient arrhythmias
or ST/T changes in ECG [8], with a pericarditis-myocar-
ditis syndrome or acute cardiac decompensation [9].
Aim of this retrospective study is to analyse the
frequency and clinico-pathological aspects of docu-
mented acute anthracycline-induced cardiotoxicity in
patients treated for acute leukemia.
Patients and methods
The medical records of 165 patients treated for acute leukemia between
1990 and 1996 at the University Hospital of Zurich. Switzerland, were
reviewed. All patients with known pre-existing heart disease, including
coronary artery disease or risk factors for it, heart disease due to the
malignancy or mediastinal radiation were excluded.
Included were patients who during or immediately after adminis-
tration of combination chemotherapy with anthracycline developed
clinical or radiological evidence oft left ventricular (LV) decompensa-
tion with dyspnea and pulmonary rales, cardiomegaly or signs of
pulmonary hypertension on chest X-ray.
Pathologic-anatomical manifestations for anthracycline associated
cardiotoxicity were hypertrophy [17, 18], cardiomegaly [17. 19], peri-
carditis [2, 7. 17, 20], pericardial effusion [17] and myocarditis [7]. The
histological criteria were myofibrillar loss, distension of the sarcoplas-
matic reticulum. and cytoplasmatic vacuolisation, diffuse cell damage
(total loss of contractile elements, loss of organellcs, milochondrial
and nuclear degeneration) [I],
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Results
In our series, six males and one female, age 19 to 66
years (median 41) met the criteria of anthracycline-
associated acute cardiotoxicity. All patients were treated
with curative intention, six for a de novo AML (FAB
classification: two patients MO, two patients Ml, one
patient M4, one patient M6) and one for relapsing
disease.
All patients but one received conventional doses of
anthracycline for treatment.
In one patient a ten-fold overdose of mitoxantrone
was accidentally infused.
Clinical course and findings
Clinical symptoms were those of left (6 of 7) or biven-
tricular heart failure (1 of 7) with dyspnea and orthopnea,
tachycardia, pulmonary oedema and elevated jugular
venous pressure. The first symptoms occured in three
patients during the first course, in three patients during
the second and in one patient after the third course of
treatment. All of them recoverd from the first episode
but six patiens died of cardiotoxicity during the following
course with anthracycline. Only one patient recovered
again.
At the time of clinical symptoms of cardiac toxicity
the chest X-ray was abnormal in all seven patients. Six
of seven had a cardiomegaly, two of seven signs of
pulmonary venous congestion and two of seven pleural
effusion. In three patients pulmonary venous congestion
as well as pleural effusion were present.
An electrocardiogram was registred in six of seven
patients before starting chemotherapy. In two of them
(P4 and P5) an incomplete right bundle branch block
was pre-existent. On treatment, a rapid atrial flutter
became manifest in one patient (PI), premature ven-
tricular complexes in another (P3). One patient (P7)
developed supraventricular arrhythmia and polymorph
premature ventricular complexes. In four patients (PI,
P4, P6 and P7) diffuse repolarisation abnormalities
appeared. In one patient an AV-block 1° occurred in
combination with a total right bundle branch block.
An echocardiography was done in three patients
(PI, P4, and P6) after the occurrence of cardiac abnor-
malities: two patients (PI, P4) had a haemodynamically
not relevant pericardial effusions with normal ejection
fraction, one patient (P6) a decreased ejection fraction
of 30%.
Treatment and outcome
Six patients (PI, P3-7) needed specific heart failure
treatment with diuretics, angiotensin converting enzyme
inhibitors (P4, P6) and catecholamines (P3, P5, P6).
Three patients received digitalis (PI, P6, P7), and one
patient (P7) lidocaine.
All seven patients died 65-450 (median 129) days
after start of chemotherapy. The death of six patients
Table I. Chemotherapy total dose mg/m2.
Pt
IM
2M
3M
4M
5M
6M
7F
DNR
288
135
135
135
135
Ida
36
80
Mito
80
42.4
450"
140
Ara-C
26265
8700
10544
25400
21400
15400
1900
VCR
0,8
0,75
m-
AMSA
618
600
720
360
VP-16
403
400
1000
Abbreviations: DNR - daunorubicin; Ida - idarubicine; Milo -
mitoxantrone: Ara-C - cytosinarabinoside: VCR - vincristine;
m-AMSA - amsacnne; VP16 - etoposide.
a
 Ten-fold overdose.
Table 2. Cardiac findings.
Pt
IM
2M
3M
4M
5M
6M
7F
Clin. signs
of conges-
tive heart
failure
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Abnormal
chest
X-ray"
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Abnormal
ECG"
Yes
No
Yes
Yes
Yes
Yes
Yes
Abnormal
echo"
Yes
nd
nd
Yes
nd
Yes
nd
Time of
death after
start of
treatment
69 d
129 d
65 d
88 d
147 d
266 d
450 d
Abbreviation: nd - not done.
a
 For details see text.
Table 3. Autopsy results" (n = 6).
Myocardial fibrosis
Endomyocardial fibrosis
Hypertrophy
Dilatation
Pericardial effusion
Peri-/epicarditis
Subendocardial haemorrhage
Myocardial necrosis
" For details see text.
was due to acute cardiotoxicity. Anthracycline-associ-
ated cardiopathy was confirmed by histo-pathological
findings. One patient recovered from a clinically well
documented episode of severe heart failure but died later
from progressing disease. An autopsy was refused.
Autopsy
Autopsy was performed in six of seven patients (P1-P5,
P7). Macroscopically, the heart was hypertrophic in all
six patients, dilatated in three (P4, P5, P7). In four (PI,
P2, P4, P5) pericardial effusion was present. A fibrous,
sterile peri-/epicarditis was seen in one (PI), epicardial
bleeding in two (P3, P4), endocardial haemorrhage in
one (P3) patient. Microscopically typical morphological
features of acute anthracycline-induced cardiotoxicity
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such as myocardial fibrosis and perinuclear vacuolisated
myocytes were seen in five patients (PI, P2, P4, P5, P7).
One (P3) had endomyocardial fibrosis. In three patients
(P3, P4, P7) myocardial necrosis was seen: in one
(P3) myocardial necrosis was subendocardial, in one
(P7) diffuse and one patient (P2) had papillary muscle
necrosis. All six patients had normal, wide coronary
arteries. Additionally, one patient (P3) had a sterile
abscess (diameter 3 mm) in the left ventricle of unknown
aetiology.
Discussion
Over a period of six years, 165 patients were treated
for acute leukemia at the University Hospital of Zurich,
Switzerland. In seven of them, acute cardiotoxicity at-
tributable to anthracycline-based chemotherapy was
observed. This is relatively a rare complication and
probably often missed. The true incidence remains un-
known. Patients with probable subclinical acute cardio-
toxicity are missed. In this study, patients with addi-
tional cardiac risk factors were not taken into account.
The most important risk factor for the development
of chronic cardiotoxicity is the total cumulative dose.
In contrast, the event of acute cardiotoxicity is not
predictable and occurs unexpectedly. There seems to be
a large variation in individual sensitivity. Often, clini-
cians are not aware of the potential risk. Less severe
episodes are therefore missed. In our experience, the
possibility of drug-induced cardiotoxicity was taken
into consideration late in the course. One reason was
that these mostly young, previously healthy patients
without pre-existing heart disease are in reduced general
condition which is ascribed to the life-threatening dis-
ease, the aggressive treatment and its well-known side
effects. Early diagnosis could contribute to the preven-
tion of drug-induced heart failure with fatal outcome in
the acute phase, possibly also reduce the rate of chronic
or late-onset anthracycline-induced cardiotoxicity.
The main problem is the lack of reliable tests for early
detection of subclinical cardiac tissue damage. Clinical
manifestations of heart failure, ECG changes or echo-
cardiography are neither sensitive enough nor specific in
an early stage. Radioimmunoscintigraphy is sensitive,
but its specificity low. Endomyocardial biopsy examina-
tion is considered to be the most sensitive and specific
method for anthracycline-induced cardiotoxicity and for
prediction of cardiac dysfunction [12]. This method is
invasive and restricted to medical centres. Therefore, the
use for routine monitoring is limited.
There ar no reliable laboratory tests for early detection
of myocardial damage. The release of cardiac troponin T
(cTnT) as a biomarker of doxorubicin-induced chronic
cardiac injury has been evaluated in the spontaneously
hypertensive rat (SHR) model. Monitoring serum levels
of cTnT can detect doxorubicin-induced myocyte dam-
age and may prove to be useful for the non-invasive
evaluation of cardiac toxicity in humans [29]. Fink et al.
[30] evaluated 35 anthracycline-containing chemother-
apy courses in 22 children with cancer. Within 72 hours
from anthracycline therapy no increment of one of these
marker proteins was detected.
Atrial natriuretic peptide (ANP), mainly from the
atrium, and brain natriuretic peptide (BNP), mainly
from the ventricle, provide prognostic information in-
dependent of other variables associated with a poor
prognosis in patients with chronic heart failure [31].
Natriuretic peptides might be useful in the detection of
subclinical left ventricular dysfunction as indication for
cardiomyoathy [34, 35]. Their predictive value for clin-
ically relevant damage is not yet known. Prospective
studies have to prove their diagnostic benefit.
Strategies for prevention of anthracycline-associated
cardiotoxicity have to be developed. Chelating agents like
ICRF 187 (dexrazoxane) and antioxidative WR-2721
(amifostine) have been applied in combination with
anthracyclines [26, 33]. Proving their efficacy is difficult
again due to the lack of established tests recording
already minimal cardiac damage. Early administration
of the ACE inhibitor may be an other therapeutic possi-
bility.
Acute cardiotoxicity of anthracyclines is a rare, but
life-threatening event. Sensitiveness to anthracyclines is
interindividually highly variable and not predictable.
The awareness of potential adverse effects on cardiac
performance by anthracyclines may contribute to early
diagnosis and prevention of drug-induced heart failure.
Reliable tests are needed for early diagnosis of subclinical
myocardial damage in order to identify patients at risk.
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